Online inquiry

IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4245MR)

This product GTTS-WQ4245MR is a type of mRNA modified with 5-Methyl-CTP, which ecodes the monoclonal antibody that targets Factor VIII substitute gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000132.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2157
UniProt ID P00451
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ4245MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1655MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACT-017
GTTS-WQ13661MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ13122MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ15808MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ3296MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ10318MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ14024MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-3500
GTTS-WQ6305MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CS-1008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW